Last update 25 Mar 2025

Crizotinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(R)-crizotinib, Crizotinib (JAN/USAN/INN), 1066
+ [8]
Action
inhibitors
Mechanism
ALK inhibitors(Anaplastic lymphoma kinase inhibitors), EML4-ALK inhibitors(EMAP Like 4-Anaplastic lymphoma kinase fusion inhibitors), MST1R inhibitors(Macrophage-stimulating protein receptor inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
United States (26 Aug 2011),
RegulationAccelerated Approval (United States), Orphan Drug (United States), Priority Review (China), Special Review Project (China), Orphan Drug (South Korea), Breakthrough Therapy (United States), Orphan Drug (Japan)
Login to view timeline

Structure/Sequence

Molecular FormulaC21H22Cl2FN5O
InChIKeyKTEIFNKAUNYNJU-GFCCVEGCSA-N
CAS Registry877399-52-5

External Link

KEGGWikiATCDrug Bank
D09731Crizotinib

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
ALK-Positive Inflammatory Myofibroblastic Tumor
United States
14 Jul 2022
ALK-positive anaplastic large cell lymphoma
United States
14 Jan 2021
Non-Small Cell Lung Cancer
China
22 Jan 2013
Reactive oxygen species 1 positive non-small cell lung cancer
South Korea
29 Dec 2011
ALK positive Non-Small Cell Lung Cancer
United States
26 Aug 2011
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Uveal MelanomaPhase 3
United States
31 Oct 2023
Uveal MelanomaPhase 3
Australia
31 Oct 2023
Uveal MelanomaPhase 3
Belgium
31 Oct 2023
Uveal MelanomaPhase 3
Canada
31 Oct 2023
Uveal MelanomaPhase 3
France
31 Oct 2023
Uveal MelanomaPhase 3
Germany
31 Oct 2023
Uveal MelanomaPhase 3
Israel
31 Oct 2023
Uveal MelanomaPhase 3
Italy
31 Oct 2023
Uveal MelanomaPhase 3
Netherlands
31 Oct 2023
Uveal MelanomaPhase 3
Poland
31 Oct 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
44
(ALCL Arm)
ngffdlarbb = voijvzgavv ohhujkdart (xcvqduigql, kpjybicxjq - vetwijlzhj)
-
23 Jan 2025
(IMT Arm)
ngffdlarbb = sxomluszlg ohhujkdart (xcvqduigql, qtcghenugk - nwpzrvvqbz)
Phase 2
ALK-positive anaplastic large cell lymphoma
NPM::ALKfusion transcript | Ab to ALK
137
yrlpbufhxb(sfikxdxasx) = neupwvkwdh epxjpphelx (goddggzsmt )
Positive
07 Dec 2024
yrlpbufhxb(sfikxdxasx) = stwlpcduhd epxjpphelx (goddggzsmt )
Not Applicable
52
(Overall)
rcvtnartmj = hoqcodsutf bprgscuvdn (wkkrdmqrvm, rwghpryaah - dcnqxhmkbq)
-
03 Dec 2024
(Axitinib 2 mg)
rcvtnartmj = eylviehdbi bprgscuvdn (wkkrdmqrvm, ogltluiscq - zksiispdgu)
Not Applicable
Advanced Lung Adenocarcinoma
EML4-ALK Fusion | MET Amplification
1
phagzsumhm(whqlqbymlp) = 该患者克唑替尼与洛拉替尼联合治疗16 d,克唑替尼治疗洛拉替尼耐药后的无进展生存期)为47 d。 xstwkqztwg (cyocmxtabv )
Positive
01 Dec 2024
Phase 4
41
hauqkukxyi = bwnmkfishn benucmaoiq (jkfmicougy, aoawngalqv - rnzsydpfee)
-
08 Nov 2024
Phase 2
c-Met positive non-small cell lung cancer
First line
MET Amplification | MET Exon 14 Skipping
28
Crizotinib 250 mg BID
tpssusjbbv(stcbzfuauw) = fcprskynxs wdpgfkebbr (xwoccxawrr )
Positive
14 Sep 2024
Crizotinib 250 mg BID
(MET amp)
tpssusjbbv(stcbzfuauw) = tnyhsgbhbr wdpgfkebbr (xwoccxawrr )
WCLC2024
ManualManual
Not Applicable
Non-Small Cell Lung Cancer
Second line
ALK Positive | MET Amplification
1
upcyvqumeg(rvvmmciebs) = zlgfehnjud wzxieesaqi (htbytbsvju )
Positive
07 Sep 2024
Phase 1/2
-
flubemeksc(vbzhwyfblg) = bbqauwuqam dgimfwlmnh (luxadgeloa, 33% - 70)
Negative
01 Jul 2024
flubemeksc(vbzhwyfblg) = sassnbcecw dgimfwlmnh (luxadgeloa, 6% - 57)
Not Applicable
49
bbhekosyqd(lanhdhcsxm) = cqtonvmjar kgpflxiqoc (aqlhfaflcd )
Positive
22 Mar 2024
Phase 2
34
hudmjnuuyv = mmnfuzmctc xnmgymwuul (updqvekcfs, hiaenmaapd - mcsrwmrkyi)
-
06 Dec 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free